ALSO IN THIS MONTH'S ISSUE
Most Favored Nation Pricing Temporarily Halted By Courts
In late December, the courts halted President Trump’s international reference-pricing scheme, the Most Favored Nation model, saying the administration had improperly attempted to implement a radical change in Medicare reimbursement policy.
Going Public In Mid-Pandemic
Just as the COVID pandemic hit, Timber Pharma was planning on going public. But that wasn’t the only challenge the company faced in the months ahead.
5 Elements Of A Long-Term Partnership Strategy
Throughout my career, I have seen partnerships that succeed and those that fail. Through this experience, I have been able to identify what it takes to build and maintain partnerships that stand the test of time.
Benefits Of Beantown Biotech And Lessons For Life Science Leaders
I have had the opportunity to experience and contribute to the thriving life sciences industry in Massachusetts, and I can say that it has all of the components needed to ultimately bring new treatments forward for patients.
Increasing Patient Diversity In Clinical Trials
The COVID-19 pandemic has spotlighted healthcare’s biggest shortfalls. One of the most glaring problems sounds like it should be simple to resolve, but it has actually been challenging to implement — diversity in clinical trials.
BEYOND THE PRINTED PAGE
We Need To Expand How We Value Companies
During an interview for an upcoming feature in Life Science Leader, Sanjeev Redkar, Ph.D., cofounder and president of Apollomics (a biopharmaceutical company discovering and developing oncology treatments), discussed the topic of an exit strategy.
Have You Heard Of The Chinese Biopharmaceutical Association (CBA)?
While working at his first job at Human Genome Sciences in 1995, Guo-Liang Yu, Ph.D., decided to create The Chinese Biopharmaceutical Association (CBA), one of the largest Chinese American professional associations in the U.S.
What 4 Biopharma CFOs Think About The Future Of Remote Work
While we touch on remote work in Life Science Leader’s annual outlook issue, the responses in this article from four biopharmaceutical CFOs to questions on the subject shed additional light on the challenge that lies ahead for employers.